molsidomine has been researched along with Stroke in 2 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH." | 7.83 | Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study. ( Brüning, R; Ehlert, A; Heindel, W; Hesselmann, V; Jacobs, AH; Manthei, G; Pluta, RM; Ringelstein, EB; Schmidt, C; Stummer, W; Wölfer, J, 2016) |
| " In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH." | 3.83 | Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study. ( Brüning, R; Ehlert, A; Heindel, W; Hesselmann, V; Jacobs, AH; Manthei, G; Pluta, RM; Ringelstein, EB; Schmidt, C; Stummer, W; Wölfer, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ehlert, A | 1 |
| Schmidt, C | 1 |
| Wölfer, J | 1 |
| Manthei, G | 1 |
| Jacobs, AH | 1 |
| Brüning, R | 1 |
| Heindel, W | 1 |
| Ringelstein, EB | 1 |
| Stummer, W | 1 |
| Pluta, RM | 1 |
| Hesselmann, V | 1 |
| Zhang, Y | 1 |
| Rosenberg, PA | 1 |
2 other studies available for molsidomine and Stroke
| Article | Year |
|---|---|
Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Infarction; Brain Ischemia; Drug Therapy, Combinat | 2016 |
The essential nutrient pyrroloquinoline quinone may act as a neuroprotectant by suppressing peroxynitrite formation.
Topics: Animals; Brain; Cell Survival; Dose-Response Relationship, Drug; Fetus; Molsidomine; Neurons; Neurop | 2002 |